Related references
Note: Only part of the references are listed.Challenges with Novel Clinical Trial Designs: Master Protocols
Michael Cecchini et al.
CLINICAL CANCER RESEARCH (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Charu Aggarwal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Corey J. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Martin J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
National Cancer Institute Basket/Umbrella Clinical Trials MATCH, LungMAP, and Beyond
Alice P. Chen et al.
CANCER JOURNAL (2019)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial
Richard Adams et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
Geraldine O'Sullivan Coyne et al.
CURRENT PROBLEMS IN CANCER (2017)
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
Tracy L. Stockley et al.
GENOME MEDICINE (2016)
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer
G. Middleton et al.
ANNALS OF ONCOLOGY (2015)
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2015)
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2014)
Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of Master Protocols in Lung Cancer
Shakun M. Malik et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Improving Survival for Stage IV Non-small Cell Lung Cancer A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005
Daniel Morgensztern et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Share Paper
